In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Calcitonin-salmon | Natural peptide Thymosin beta-4 (human) | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Natural peptide | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 661 | 1,449 (plus 953 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 58 (58 in people) | 12 (8 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 18 · 1 active7 more mention it but do not test it | 13 · 1 active2 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Calcitonin salmon nasal spray says: “Postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Calcitonin-salmon | Thymosin beta-4 (human) |
|---|---|---|
| Bone and jointMusculoskeletal | 361346411 | 5311 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 8 Oct 2026).
| Receptor activity and mechanismPharmacology | 331221 | 310292792 |
|---|
| PharmacokineticsRespiratory | 4949 | 287183 |
|---|
| PainNervous system and cognition | 5252 | 523 |
|---|
| Adverse eventsWhole body | 4242 | 981 |
|---|
| Exercise and physical functionMusculoskeletal | 2828 | 11 |
|---|
| Kidney functionKidney and urinary | 66 | 14131 |
|---|
| Tumor growthMusculoskeletal | 44 | 20119 |
|---|
| Glycemic controlMetabolic and weight | 651 | 1010 |
|---|
| Gastrointestinal protectionGastrointestinal | 22 | 16142 |
|---|
| MortalityWhole body | 22 | 88 |
|---|
| Anxiety and moodMental health and mood | 22 | 22 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 18 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Nordic Bioscience A/S1,030 participantsJun 2008 to Jun 2011
Osteoarthritis
Tarsa Therapeutics, Inc.565 participantsJun 2009 to Feb 2011
Osteoporosis, Postmenopausal
Eli Lilly and Company364 participantsDec 2006 to Jul 2008
Osteoporosis
7 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 13 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ReGenTree, LLC700 participants24 May 2019 to 7 Oct 2021
Dry Eye Syndromes · Dry Eye
ReGenTree, LLC601 participantsNov 2016 to Mar 2018
Dry Eye Syndrome
ReGenTree, LLC18 participants17 Sept 2015 to 9 Mar 2020
Neurotrophic Keratopathy
2 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Calcitonin-salmon | Thymosin beta-4 (human) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | 3% Lumbar BMD change from baseline Dose studied: 200 IU daily, 1 month on-1 month off1 yearn = 912005 | No randomized trial result 53 results from other study designs. |
3%
Lumbar BMD change from baseline
Dose studied: 200 IU daily, 1 month on-1 month off1 yearn = 912005
No randomized trial result
53 results from other study designs.